Descriptive Study of Variations in Serum Translocation Markers of the Intestinal Microbiota in Patients With Gougerot-Sjögren Syndrome According to Disease Activity (IMISS)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Radjiv Goulabchand
- Phone Number: +33 (0)7.61.39.30.82
- Email: radjiv2001@hotmail.com
Study Locations
-
-
-
Nîmes, France
- CHU de Nîmes
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- The patient must be a member or beneficiary of a health insurance plan
- Patients with primary Sjögren's syndrome according to the AECG criteria
Exclusion Criteria:
- The subject is participating in a category I interventional study, or is in a period of exclusion determined by a previous study
- It is impossible to give the subject informed information
- The patient is under safeguard of justice or state guardianship
- Pregnant, parturient or breastfeeding patients
- Patients with secondary Sjögren's syndrome
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients with Sjögren Syndrome
|
Quantification of serum markers of intestinal permeability and bacterial and fungal translocation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference in Intestinal Fatty Acid Binding Protein (I-FABP) levels from baseline in patients passing to a different level of disease activity
Time Frame: Upon changing disease activity level (maximum 3 years)
|
ng/ml measured by ELISA; Change in disease activity levels defined by 3-point change on the European League Against Rheumatism Sjögren Syndrome Disease Activity Index (ESSDAI)
|
Upon changing disease activity level (maximum 3 years)
|
|
Difference in zonulin-1 levels from baseline in patients passing to a different level of disease activity
Time Frame: Upon changing disease activity level (maximum 3 years)
|
ng/ml measured by ELISA; Change in disease activity levels defined by 3-point change on the European League Against Rheumatism Sjögren Syndrome Disease Activity Index (ESSDAI)
|
Upon changing disease activity level (maximum 3 years)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference in LPS-binding Protein levels from baseline in patients passing to a different level of disease activity
Time Frame: Upon changing disease activity level (maximum 3 years)
|
pg/ml, measured by ELISA; Change in disease activity levels defined by 3-point change on the European League Against Rheumatism Sjögren Syndrome Disease Activity Index (ESSDAI)
|
Upon changing disease activity level (maximum 3 years)
|
|
Difference in LPS-binding Protein levels from baseline in patients reporting an improvement in disease activity
Time Frame: Upon changing disease activity level (maximum 3 years)
|
pg/ml, measured by ELISA; patient-reported disease severity defined by 1-point increase on the European League Against Rheumatism Sjögren's syndrome Patient Reported Index (ESSPRI)
|
Upon changing disease activity level (maximum 3 years)
|
|
Difference in LPS-binding Protein levels between patients receiving or not systemic treatment (corticosteroids, plaquenil or methotrexate)
Time Frame: Upon changing disease activity level (maximum 3 years)
|
pg/ml, measured by ELISA
|
Upon changing disease activity level (maximum 3 years)
|
|
Difference in soluble CD14 levels from baseline in patients passing to a different level of disease activity
Time Frame: Upon changing disease activity level (maximum 3 years)
|
ng/ml, measured by ELISA; Change in disease activity levels defined by 3-point change on the European League Against Rheumatism Sjögren Syndrome Disease Activity Index (ESSDAI)
|
Upon changing disease activity level (maximum 3 years)
|
|
Difference in soluble CD14 levels from baseline in patients reporting an improvement in disease activity
Time Frame: Upon changing disease activity level (maximum 3 years)
|
ng/ml, measured by ELISA; patient-reported disease severity defined by 1-point increase on the European League Against Rheumatism Sjögren's syndrome Patient Reported Index (ESSPRI)
|
Upon changing disease activity level (maximum 3 years)
|
|
Difference in soluble CD14 levels between patients receiving or not systemic treatment (corticosteroids, plaquenil or methotrexate)
Time Frame: Upon changing disease activity level (maximum 3 years)
|
ng/ml, measured by ELISA
|
Upon changing disease activity level (maximum 3 years)
|
|
Difference in fungal 18s RNA levels from baseline in patients passing to a different level of disease activity
Time Frame: Upon changing disease activity level (maximum 3 years)
|
PCR and sequencing; Change in disease activity levels defined by 3-point change on the European League Against Rheumatism Sjögren Syndrome Disease Activity Index (ESSDAI)
|
Upon changing disease activity level (maximum 3 years)
|
|
Difference in fungal 18s RNA levels from baseline in patients reporting an improvement in disease activity
Time Frame: Upon changing disease activity level (maximum 3 years)
|
PCR and sequencing; patient-reported disease severity defined by 1-point increase on the European League Against Rheumatism Sjögren's syndrome Patient Reported Index (ESSPRI)
|
Upon changing disease activity level (maximum 3 years)
|
|
Difference in fungal 18s RNA levels between patients receiving or not systemic treatment (corticosteroids, plaquenil or methotrexate)
Time Frame: Upon changing disease activity level (maximum 3 years)
|
PCR and sequencing
|
Upon changing disease activity level (maximum 3 years)
|
|
Difference in bacterial 16s RNA levels from baseline in patients passing to a different level of disease activity
Time Frame: Upon changing disease activity level (maximum 3 years)
|
PCR and sequencing; Change in disease activity levels defined by 3-point change on the European League Against Rheumatism Sjögren Syndrome Disease Activity Index (ESSDAI)
|
Upon changing disease activity level (maximum 3 years)
|
|
Difference in bacterial 16s RNA levels from baseline in patients reporting an improvement in disease activity
Time Frame: Upon changing disease activity level (maximum 3 years)
|
PCR and sequencing; patient-reported disease severity defined by 1-point increase on the European League Against Rheumatism Sjögren's syndrome Patient Reported Index (ESSPRI)
|
Upon changing disease activity level (maximum 3 years)
|
|
Difference in bacterial 16s RNA levels between patients receiving or not systemic treatment (corticosteroids, plaquenil or methotrexate)
Time Frame: Upon changing disease activity level (maximum 3 years)
|
PCR and sequencing
|
Upon changing disease activity level (maximum 3 years)
|
|
EQ-5D-5L questionnaire
Time Frame: Baseline
|
score 0-100
|
Baseline
|
|
EQ-5D-5L questionnaire
Time Frame: Upon changing disease activity level (maximum 3 years)
|
score 0-100
|
Upon changing disease activity level (maximum 3 years)
|
|
World Health Organization Quality Of Life BREF questionnaire
Time Frame: Baseline
|
score 0-100
|
Baseline
|
|
World Health Organization Quality Of Life BREF questionnaire
Time Frame: Upon changing disease activity level (maximum 3 years)
|
score 0-100
|
Upon changing disease activity level (maximum 3 years)
|
|
Hospital Anxiety and Depression Scale
Time Frame: Baseline
|
score 0-42
|
Baseline
|
|
Hospital Anxiety and Depression Scale
Time Frame: Upon changing disease activity level (maximum 3 years)
|
score 0-42
|
Upon changing disease activity level (maximum 3 years)
|
|
Multidimensional Fatigue Inventory
Time Frame: Baseline
|
score 4-20
|
Baseline
|
|
Multidimensional Fatigue Inventory
Time Frame: Upon changing disease activity level (maximum 3 years)
|
score 4-20
|
Upon changing disease activity level (maximum 3 years)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Radjiv Goulabchand, CHU Nîmes
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Musculoskeletal Diseases
- Mouth Diseases
- Stomatognathic Diseases
- Arthritis
- Joint Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Autoimmune Diseases
- Immune System Diseases
- Eye Diseases
- Arthritis, Rheumatoid
- Xerostomia
- Salivary Gland Diseases
- Dry Eye Syndromes
- Lacrimal Apparatus Diseases
- Skin and Connective Tissue Diseases
- Sjogren's Syndrome
Other Study ID Numbers
Other Study ID Numbers
- NIMAO/2019-01/RG-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.